Literature DB >> 9926930

Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31.

M Simoneau1, T O Aboulkassim, H LaRue, F Rousseau, Y Fradet.   

Abstract

The most common genetic alteration identified in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9. However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preamplification (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only five (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with superficial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identified at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-1, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These findings suggest four target regions on 9q within which suppressor genes for TCC may reside.

Entities:  

Mesh:

Year:  1999        PMID: 9926930     DOI: 10.1038/sj.onc.1202277

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  A new microRNA target prediction tool identifies a novel interaction of a putative miRNA with CCND2.

Authors:  Anastasis Oulas; Nestoras Karathanasis; Annita Louloupi; Ioannis Iliopoulos; Kriton Kalantidis; Panayiota Poirazi
Journal:  RNA Biol       Date:  2012-09-01       Impact factor: 4.652

Review 3.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

4.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 5.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

6.  An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells.

Authors:  Yusuke Yamamoto; Yusuke Yoshioka; Kaho Minoura; Ryou-u Takahashi; Fumitaka Takeshita; Toshiki Taya; Reiko Horii; Yayoi Fukuoka; Takashi Kato; Nobuyoshi Kosaka; Takahiro Ochiya
Journal:  Mol Cancer       Date:  2011-11-03       Impact factor: 27.401

7.  MiRduplexSVM: A High-Performing MiRNA-Duplex Prediction and Evaluation Methodology.

Authors:  Nestoras Karathanasis; Ioannis Tsamardinos; Panayiota Poirazi
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 8.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

9.  Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma.

Authors:  Satyabrata Sinha; Ratnesh K Singh; Neyaz Alam; Anup Roy; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  Mol Cancer       Date:  2008-11-06       Impact factor: 27.401

10.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.